Brevan Howard Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Brevan Howard Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$562K	Sell	9,954 -10,076	-50%	-$587K	0.01%	1225
2025 Q4	$1.19M	Sell	20,030 -2,175	-10%	-$118K	0.01%	688
2025 Q3	$1.2M	Buy	+22,205	New	+$1.27M	0.01%	813
2024 Q4	–	Sell	-9,218	Closed	-$648K	–	1063
2024 Q3	$648K	Buy	+9,218	New	+$771K	﹤0.01%	613
2024 Q2	–	Sell	-9,197	Closed	-$803K	–	1081
2024 Q1	$803K	Buy	+9,197	New	+$823K	0.01%	322

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brevan Howard Capital Management's BMRN Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 50% in Q1 2026, selling an estimated $587K and leaving 9,954 shares worth $562K. The position accounts for 0.01% of the portfolio, ranked #1225.

Brevan Howard Capital Management first reported a position in BMRN in Q1 2024 and has held it in 5 quarters since. The position peaked at $1.2M in Q3 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Brevan Howard Capital Management held 9,954 shares of BioMarin Pharmaceuticals worth $562K as of Q1 2026.
Brevan Howard Capital Management sold 10,076 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $587K.
BioMarin Pharmaceuticals made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1225 holding.
Brevan Howard Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
Brevan Howard Capital Management's BioMarin Pharmaceuticals position peaked at $1.2M in Q3 2025.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.